durvalumab,paclitaxel,carboplatin,cisplatin,gemcitabine,pemetrexed
astrazeneca
['nsclc', 'aegean', 'sclc']
aegean trial shows a 32% reduction in the risk of disease recurrence or progression in nsclc #aacr23
Onco’Zine reports about current research and development in hematology and oncology.